Heidelberg Pharma AG

XTRA:HPHA 株式レポート

時価総額：€124.4m

Heidelberg Pharma 配当と自社株買い

配当金 基準チェック /06

Heidelberg Pharma配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-15.1%

バイバック利回り

総株主利回り-15.1%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

ナラティブの更新 • May 30

HPHA: Phase II Expansion Will Drive Future Upside Despite Going Concern Risks

Analysts now set a lower price target for Heidelberg Pharma, moving it from €6.75 to €5.50, as updated assumptions point to a very large future P/E multiple alongside tempered revenue growth expectations and a slimmer profit margin outlook. What's in the News Auditor Baker Tilly issued an unqualified opinion on the latest annual report but raised doubts about Heidelberg Pharma's ability to continue as a going concern, flagging liquidity and financing as key risk areas (Annual filing, period ending 30 Nov 2025).
ナラティブの更新 • May 11

HPHA: Phase II Expansion And China Milestone Will Support Future Upside

Analysts have maintained their €6.75 price target for Heidelberg Pharma, citing slightly adjusted model assumptions regarding the discount rate, revenue growth and future P/E to reflect updated expectations, while keeping their overall valuation view unchanged. What's in the News Auditor Baker Tilly issued an unqualified opinion on Heidelberg Pharma's annual report for the period ending 30 November 2025, while expressing doubt about the company's ability to continue as a going concern.
ナラティブの更新 • Apr 22

HPHA: Phase II Dose Selection And China Milestone Will Support Future Upside

Analysts have kept their €6.75 price target for Heidelberg Pharma unchanged, noting only minor adjustments in the discount rate and future P/E assumptions while maintaining their existing fair value view. What's in the News Heidelberg Pharma set the recommended Phase II dose for its lead candidate pamlectabart tismanitin (HDP-101) in a Phase I/IIa study for relapsed or refractory multiple myeloma, after a review found the drug was well tolerated at evaluated dose levels and a maximum tolerated dose was not reached (Product-Related Announcements).
新しいナラティブ • Apr 16

Single Lead ADC And Funding Risks Will Dominate Near Term But Platform Potential May Emerge

Catalysts About Heidelberg Pharma Heidelberg Pharma develops antibody drug conjugates that use its proprietary Amanitin payload technology for cancer treatment. What are the underlying business or industry changes driving this perspective?
ナラティブの更新 • Apr 08

HPHA: Chinese Trial Milestone Will Support Future Upside From Undervalued Levels

Analysts have maintained their price target for Heidelberg Pharma at €6.75, citing updated assumptions that combine a very large projected revenue growth rate with an unchanged profit margin and a lower future P/E multiple. What's in the News Heidelberg Pharma plans to present preclinical data for its Amanitin-based ADC candidate HDP-103 for metastatic castration-resistant prostate cancer at the AACR Annual Meeting 2026 in San Diego, with a poster session scheduled on 21 April from 2:00 pm to 5:00 pm PDT (company announcement).
新しいナラティブ • Apr 01

Amanitin ADC Platform And ADC Market Expansion Will Support Strong Long Term Potential

Catalysts About Heidelberg Pharma Heidelberg Pharma is a biotechnology company focused on developing antibody drug conjugates based on its proprietary Amanitin payload technology. What are the underlying business or industry changes driving this perspective?
ナラティブの更新 • Mar 24

HPHA: Chinese Trial Milestone Will Support Future Upside From Undervalued Levels

Analysts have kept their €6.75 price target for Heidelberg Pharma broadly unchanged, citing only marginal shifts in inputs such as the discount rate, long term profit margin assumptions and future P/E, which together leave their overall valuation view effectively steady. What's in the News Huadong Medicine has reached a development milestone under its 2022 license agreement with Heidelberg Pharma, triggering a milestone payment to Heidelberg Pharma, with financial details not disclosed (company announcement).
ナラティブの更新 • Mar 08

HPHA: Steady Assumptions And Undervalued Outlook Will Support Future Upside

Analysts are keeping their price target for Heidelberg Pharma steady at €6.75. They cite only marginal tweaks to their discount rate and long term assumptions for revenue growth, profit margin and future P/E, rather than any shift in their core view on the stock.
ナラティブの更新 • Feb 21

HPHA: New Leadership And High Growth Assumptions Will Support Future Upside

Analysts have kept their price target for Heidelberg Pharma steady at €6.75, with only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions supporting this unchanged view. What's in the News The Supervisory Board revoked the appointment of Professor Andreas Pahl as Chief Executive Officer of Heidelberg Pharma AG, effective immediately (Key Developments).
ナラティブの更新 • Feb 07

HPHA: Leadership Transition And Stable Outlook Will Support Future Upside

Analysts have kept their price target for Heidelberg Pharma steady at €6.75. They point to only small shifts in inputs such as the discount rate and the assumed future P/E multiple as reasons for maintaining their existing view.
ナラティブの更新 • Jan 24

HPHA: Positive Trial Data And New Leadership Will Support Future Upside

Analysts have revised their price target for Heidelberg Pharma from €10.56 to €6.75, citing updated assumptions for revenue growth, profit margins, discount rates, and future P/E that change their assessment of the company’s risk profile and earnings potential. What's in the News The Supervisory Board revoked the appointment of Professor Andreas Pahl as Chief Executive Officer and appointed Dr Dongzhou Jeffery Liu as the new CEO with immediate effect.
User avatar
新しいナラティブ • Apr 13

ATAC Platform And HDP-101 Trials Will Advance Clinical Frontiers

Heidelberg Pharma's ATAC technology and multiple pipeline candidates offer potential for new revenue streams and long-term growth in earnings.
分析記事 • Feb 16

Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Dec 05

Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Heidelberg Pharma AG's ( ETR:HPHA ) price-to-sales (or "P/S") ratio of 15x might make it look like a strong sell right...
分析記事 • Jul 21

Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Celebrations may be in order for Heidelberg Pharma AG ( ETR:HPHA ) shareholders, with the analysts delivering a...
分析記事 • Oct 16

Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher

Heidelberg Pharma AG ( ETR:HPHA ) shareholders will have a reason to smile today, with the analysts making substantial...
分析記事 • Nov 28

Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
分析記事 • Mar 27

Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be

The analysts covering Heidelberg Pharma AG ( ETR:HPHA ) delivered a dose of negativity to shareholders today, by making...
分析記事 • Mar 15

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, Heidelberg Pharma...
分析記事 • Jan 17

Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

Heidelberg Pharma AG ( ETR:HPHA ) shareholders might be concerned after seeing the share price drop 14% in the last...
分析記事 • Dec 14

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

決済の安定と成長

配当データの取得

安定した配当: HPHAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: HPHAの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Heidelberg Pharma 配当利回り対市場
HPHA 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (HPHA)n/a
市場下位25% (DE)1.5%
市場トップ25% (DE)4.7%
業界平均 (Biotechs)2.4%
アナリスト予想 (HPHA) (最長3年)0%

注目すべき配当: HPHAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: HPHAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: HPHAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: HPHAが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/10 22:49
終値2026/07/10 00:00
収益2026/02/28
年間収益2025/11/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Heidelberg Pharma AG 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9

アナリスト機関
Bruno BulicBaader Helvea Equity Research
Christian WeizBaader Helvea Equity Research
Robin DavisonEdison Investment Research